Arca
Skip to content
Tools
Tools

Hepatitis B

Drug research and approvals for hepatitis B: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 146 studies of hepatitis B are recruiting on ClinicalTrials.gov, Health Canada has authorized 47 drug trials for it since 2013, FDA has 2 approved and 9 open orphan designations naming it, and the EU has 17 authorised medicines for it.

  • Recruiting worldwide: 146
  • Trials authorized in Canada: 47
  • FDA orphan approvals: 2
  • EU medicines: 17

Recruiting now

Newest posted first, of 146 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 8

Phase 1 or earlier 5

How its trials ended

1,674 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 397 whose ending is known, 59% met their primary endpoint, 6% missed it and 35% stopped early.

  • Completed, result not reported64639%
  • Status unknown38923%
  • Ongoing24214%
  • Met its primary endpoint23514%
  • Stopped: other or unclear754%
  • Stopped: sponsor or business decision292%
  • Missed its primary endpoint221%
  • Stopped: enrollment or feasibility221%
  • Stopped: lack of efficacy7<1%
  • Stopped: safety7<1%

Trials authorized in Canada

The 10 newest of 47; search them all in Canada trials
Oct 2, 2026A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of AZD6750 in participants with chronic hepatitis B on standard…AZD6750AstraZeneca PharmaceuticalsPending
Jul 22, 2026A phase 2 multi-center, randomized, open-label study to assess the efficacy and safety of AHB-137 in nucleos(t)ide analogue-treated participants with chronic…AHB-137Ausperbio Therapeutics Inc.Pending
May 14, 2025A randomized, double-blind, active-controlled multicenter phase 2 study evaluating the efficacy and safety of ALG-000184 compared with tenofovir disoproxil…Pevifoscorvir sodium (ALG-000184) / Tenofovir disoproxilAligos TherapeuticsOngoing
Nov 6, 2024A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of…AB-101Arbutus BiopharmaClosed
Sep 23, 2024A phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with…Bepirovirsen (GSK3228836) / Daplusiran-tomligisiran (GSK5637608/JNJ-73763989)GSKOngoing
Jul 2, 2024A multicenter, randomized, double-blind, placebo- controlled study to assess the efficacy and safety of treatment with bepirovirsen in participants living with…Bepirovirsen (GSK3228836)GSKOngoing
Mar 28, 2024Four-part, randomized, double-blind (parts 1, 2a, 3 and 4), multi-center, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and…Bepirovirsen (GSK3228836) / GSK3965193GSKClosed
Aug 11, 2023Phase II investigator-initiated study to understand the vaccinal effect of hbsag monoclonal ab VIR-3434 in chronic hepatitis B infectionVIR-3434University Health NetworkOngoing
Dec 16, 2022A phase 2 study to evaluate the safety, tolerability, and efficacy of regimens containing VIR-2218, VIR-3434, and/or peg-ifn in subjects with chronic hepatitis…Elebsiran (VIR-2218)/ Tobevibart (VIR-3434)/ Peginterferon ALFA-2AVir BiotechnologyOngoing
Nov 9, 2022Phase 3 multicenter, randomized, double-blind, study to assess the efficacy and safety of treatment with bepirovirsen in nucleos(t)ide analogue treated…Bepirovirsen (GSK3228836)GSKClosed

FDA orphan designations

Approved first, then open designations, newest first
Jan 25, 2024KeytrudaTreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a…MSD International Business GmbHApproved
Apr 6, 2007HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patientsCangene CorporationApproved
Feb 20, 2018Tenofovir exalidexTreatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age)ContraVir Pharmaceuticals, Inc.Designated
May 6, 2013Hepatitis B virus neutralizing human monoclonal antibodyPrevention of hepatitis B recurrence following liver transplantationGreen Cross Corp.Designated
Jul 15, 2003Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab…For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantationCubist PharmaceuticalsDesignated
Mar 8, 1995Hepatitis B immune globulin intravenous (human)Prophylaxis against hepatitis B virus reinfection in liver transplant patients.Biotest Pharmaceuticals CorporationDesignated
Mar 16, 1994Immunotherapeutic vaccine consisting of…Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.Cytel CorporationDesignated
Jul 24, 1992FialuridineAdjunctive treatment of chronic active hepatitis B.Oclassen Pharmaceuticals, Inc.Designated
Jun 17, 1991Monoclonal antibody to hepatitis B virus (human)Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.Protein Design Labs, Inc.Designated
May 3, 1991ThymalfasinTreatment of chronic active hepatitis BSciClone Pharmaceuticals, Inc.Designated
Nov 17, 1988Interferon alfa-2b (recombinant)Treatment of acute hepatitis B.Schering CorporationDesignated

Medicines authorised in the EU

Newest first; 15 of 17
Feb 18, 2021Heplisav BHepatitis B surface antigenDynavax GmbHEMA ↗
Sep 25, 2017Entecavir AccordEntecavir · genericAccord Healthcare S.L.U.EMA ↗
Sep 18, 2017Entecavir Viatris (previously Entecavir Mylan)Entecavir · genericViatris LimitedEMA ↗
Jan 9, 2017VemlidyTenofovir alafenamideGilead Sciences Ireland UCEMA ↗
Feb 15, 2016VaxelisDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)MCM Vaccine B.V.EMA ↗
Apr 17, 2013HexacimaDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)Sanofi Winthrop IndustrieEMA ↗
Apr 17, 2013HexyonDiphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)Sanofi Winthrop IndustrieEMA ↗
Nov 30, 2009ZutectraHuman hepatitis B immunoglobulinBiotest Pharma GmbHEMA ↗
Oct 23, 2009Lamivudine TevaLamivudine · genericTeva B.V.EMA ↗
Jun 26, 2006BaracludeEntecavirBristol-Myers Squibb Pharma EEIGEMA ↗
Feb 2, 2005FendrixHepatitis B (rDNA) vaccine (adjuvanted, adsorbed)GlaxoSmithKline Biologicals S.A.EMA ↗
Aug 30, 2002AmbirixHepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)GlaxoSmithKline Biologicals S.A.EMA ↗
Feb 4, 2002VireadTenofovir disoproxilGilead Sciences Ireland UCEMA ↗
Apr 27, 2001HBVaxProHepatitis B vaccine (recombinant DNA)Merck Sharp & Dohme B.V.EMA ↗
Oct 23, 2000Infanrix HexaDiphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed)GlaxoSmithKline Biologicals S.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.